38LOW

OSL

ONCOSIL FPO [OSL]
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company's lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
Healthcare · ASX Small Cap
$0.5150 -1.0%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical58
Catalyst65
Sentiment50
Fundamental81
Momentum46
Risk Gate50
Get alerts when OSL's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track OSL — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • MACD just crossed bullish — momentum is shifting to the upside
  • Smart money may be accumulating — volume is flowing in even though price hasn't moved yet
  • Lagging the Small Ords index — relative strength of 0.89, underperforming its peers
  • Critical cash runway (0.9 quarters)
  • Low P/S ratio (4.2x)
  • Strong revenue growth (+222%)
  • EPS estimates revised upward (+10pts)
  • Near 52-week low (4% of range)
  • Micro-cap ($5-20M) - high risk
  • New substantial holder(s) (1)
  • CANSLIM S: Tight float (48%)
  • CANSLIM I: Institutional ownership (35%)
  • Sentiment is mixed — no strong consensus either way
  • Revenue growing at +222% — the top line is moving in the right direction
  • Beneish M-Score -1.60 > -1.78: likely earnings manipulation
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • The bigger volume days are the down days — volume-weighted momentum is negative (-1.43%/day)
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about OSL
"What's driving OSL's score?" "How does OSL compare to peers?" "Key risks for OSL?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Change in substantial holding from SOL
NONE Change in substantial holding from PCG
NONE Change of Director's Interest Notice X2
HIGH Becoming a substantial holder
Announcement tone +3pts

Recent ASX Announcements

2026-03-20 Change in substantial holding from SOL
2026-03-19 Becoming a substantial holder
2026-03-19 Change in substantial holding from PCG
2026-03-19 Change of Director's Interest Notice X2
2026-03-19 Late Lodgement of Appendix 3Y

Key Metrics

$15.8M
Market Cap
59K
Avg Volume
1.9x
Vol Ratio
$0.46 — $2.09
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-208.4%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandpassFloat: 48%
LLeader vs LaggardlaggardRS: -10
IInstitutional SponsorshippassInst: 35%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #99 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:OSL vs ATXOSL vs PNVOSL vs IMM
Scout Pro — Deeper Analysis for OSL
Try Pro free for 30 days
Share this analysis

Track OSL and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required